NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
ICICI Securities expects Metropolis Healthcare Ltd. to register an earnings CAGR of 29% over FY26β28E with revenue CAGR at ~15%.
Revenue growth is likely to stem from volume growth (9β10%) while test mix and realisation improvement may fetch the balance 5% YoY growth.
The brokerage expects Ebitda margin to expand ~230bps YoY over FY26β28E. ICICI Securities sees RoE and RoCE of 19.4% and 16.6%, respectively, in FY28E.
ALSO READ: Oil India Share Price Target Raised by ICICI Securities; Stock Remains Top Pick β Here's Why
The stock currently trades at valuations of 45.6x FY27E and 36.5x FY28E earnings and EV/Ebitda multiple of 23.9x FY27E and 19.5x FY28E.
ICICI securities has maintained its Buy with an unchanged DCF-based target price of Rs 675.
Key downside risks: Higher-than-expected competition; and regulatory hurdles.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories β On NDTV Profit.
